William R. Wolowich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
William R. Wolowich has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Devada Singh-Franco
Health Professions Division, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, USA
4 shared publications - Daisy De La Rosa
Martin and Gail Press Health Professions Division Library, Nova Southeastern University, Fort Lauderdale, USA
2 shared publications Carmen M. Hadley
1 shared publicationChristie Sathianathan
St. Boniface Hospital, Winnipeg, Canada
1 shared publicationChristine Davis
College of Pharmacy, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada
1 shared publication- Daniela Fernandez
Novo Nordisk USA Plainsboro New Jersey USA
1 shared publication
Latest Publications
- 11 November 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (12) , 1252-1265
Breaking Bias: An Interprofessional Approach to Reducing Stigma Towards Patients With Substance Use Disorders in Health Professions Education
Introduction: Addressing substance use disorders (SUD) stigma via interprofessional collaboration prior to patient exposure may empower more students to provide care to people with SUD (PwSUD) across settings. Objective: To assess the impact of a SUD interprofessional educational program (SUD‐IPEP) on medical (MS) and pharmacy students' (PS) attitudes about SUD treatment efficacy and personal characteristics of PwSUD. Methods: Between February and March 2022, 288 students completed two self‐study components and an active learning component. A 13‐item perception survey was administered pre‐IPEP and immediately post‐IPEP. The survey consisted of five positive statements about treatment efficacy (e.g., treatment is effective and worth the effort ) and the desired response was an increase in agreement with these statements. The remaining items were negative statements about the personal characteristics of PwSUD (e.g., these patients overuse health care resources and provide nothing in return ) and the desired response was an increase in disagreement. Differences between subgroups (sex and race/ethnicity) were investigated. A third survey about the program's usefulness was administered 30 days post‐IPEP. Results: The response rate to the pre‐ and post‐intervention surveys was 63.5%. At pre‐intervention, there was agreement with positive statements, with no differences among subgroups. At post‐intervention, PS showed a significant increase in agreement with statements about treatment efficacy. At pre‐intervention, there was disagreement with negative statements about PwSUD, especially by females, MS, and Whites. No changes in perceptions were observed post‐intervention for any group. Thirty‐eight students completed the 30‐day survey and 92% believed the SUD‐IPEP benefited their professional development and/or practice, while 97% expected to continue using the information in the future. Conclusions: Participation in the SUD‐IPEP resulted in a general improvement in students' perceptions towards this patient population. Future studies should include whether additional educational components can help shift perceptions to reduce stigma towards PwSUD.
- 11 November 2025
- Published by Wiley in JACCP: Journal of the American College of Clinical Pharmacy
- Vol. 8 (12) , 1252-1265
Breaking Bias: An Interprofessional Approach to Reducing Stigma Towards Patients With Substance Use Disorders in Health Professions Education
Introduction: Addressing substance use disorders (SUD) stigma via interprofessional collaboration prior to patient exposure may empower more students to provide care to people with SUD (PwSUD) across settings. Objective: To assess the impact of a SUD interprofessional educational program (SUD‐IPEP) on medical (MS) and pharmacy students' (PS) attitudes about SUD treatment efficacy and personal characteristics of PwSUD. Methods: Between February and March 2022, 288 students completed two self‐study components and an active learning component. A 13‐item perception survey was administered pre‐IPEP and immediately post‐IPEP. The survey consisted of five positive statements about treatment efficacy (e.g., treatment is effective and worth the effort ) and the desired response was an increase in agreement with these statements. The remaining items were negative statements about the personal characteristics of PwSUD (e.g., these patients overuse health care resources and provide nothing in return ) and the desired response was an increase in disagreement. Differences between subgroups (sex and race/ethnicity) were investigated. A third survey about the program's usefulness was administered 30 days post‐IPEP. Results: The response rate to the pre‐ and post‐intervention surveys was 63.5%. At pre‐intervention, there was agreement with positive statements, with no differences among subgroups. At post‐intervention, PS showed a significant increase in agreement with statements about treatment efficacy. At pre‐intervention, there was disagreement with negative statements about PwSUD, especially by females, MS, and Whites. No changes in perceptions were observed post‐intervention for any group. Thirty‐eight students completed the 30‐day survey and 92% believed the SUD‐IPEP benefited their professional development and/or practice, while 97% expected to continue using the information in the future. Conclusions: Participation in the SUD‐IPEP resulted in a general improvement in students' perceptions towards this patient population. Future studies should include whether additional educational components can help shift perceptions to reduce stigma towards PwSUD.
- Open Access
- 5 April 2025
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 50 (3) , 229-242
Pharmacokinetic/Pharmacodynamic Modeling of the Acute Heart Rate Effects of Delta-9 Tetrahydrocannabinol and Its Major Metabolites After Intravenous Injection in Healthy Volunteers
Background and Objectives Cannabis consumption is increasing in both the recreational and medical settings. Tetrahydrocannabinol (THC) is known to produce cardiovascular effects, but the specific roles of THC and its metabolites THC-OH and THC-COOH in cannabinoid-induced cardiovascular effects remain unclear. We hypothesized that THC and THC-OH mediate a cannabinoid-induced increase in heart rate in either an additive or synergistic fashion. Methods The present study uses prospectively obtained data to evaluate the effect of THC and its metabolites on heart rate in healthy volunteers through non-linear mixed-effect pharmacokinetic/pharmacodynamic (PK/PD) modeling. Results The PK/PD models reveal that THC, THC-OH and a combination of THC and THC-OH, but not THC-COOH, are responsible for THC-induced tachycardia. The EC50 of the THC Emax model was 0.53 µM, 25-fold the EC50 for the THC-OH Emax model. The General Empiric Dynamic Model indicates that THC and THC-OH act synergistically to increase heart rate. Neither sex nor CYP2C9 polymorphism contributes to THC-induced tachycardia. Conclusion THC-OH but not THC-COOH contributes to the heart rate effect of THC and THC-OH may be acting in a synergistic manner with THC. This contributes to understanding the cardiovascular effects of THC and cannabis-induced cardiovascular events. Future research including further hemodynamic data will allow a detailed systems pharmacology or response surface model approach. Trial registration www.isrctn.com; registration number ISRCTN53019164.
- 5 April 2025
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 50 (3) , 229-242
Open AccessPharmacokinetic/Pharmacodynamic Modeling of the Acute Heart Rate Effects of Delta-9 Tetrahydrocannabinol and Its Major Metabolites After Intravenous Injection in Healthy Volunteers
Background and Objectives Cannabis consumption is increasing in both the recreational and medical settings. Tetrahydrocannabinol (THC) is known to produce cardiovascular effects, but the specific roles of THC and its metabolites THC-OH and THC-COOH in cannabinoid-induced cardiovascular effects remain unclear. We hypothesized that THC and THC-OH mediate a cannabinoid-induced increase in heart rate in either an additive or synergistic fashion. Methods The present study uses prospectively obtained data to evaluate the effect of THC and its metabolites on heart rate in healthy volunteers through non-linear mixed-effect pharmacokinetic/pharmacodynamic (PK/PD) modeling. Results The PK/PD models reveal that THC, THC-OH and a combination of THC and THC-OH, but not THC-COOH, are responsible for THC-induced tachycardia. The EC50 of the THC Emax model was 0.53 µM, 25-fold the EC50 for the THC-OH Emax model. The General Empiric Dynamic Model indicates that THC and THC-OH act synergistically to increase heart rate. Neither sex nor CYP2C9 polymorphism contributes to THC-induced tachycardia. Conclusion THC-OH but not THC-COOH contributes to the heart rate effect of THC and THC-OH may be acting in a synergistic manner with THC. This contributes to understanding the cardiovascular effects of THC and cannabis-induced cardiovascular events. Future research including further hemodynamic data will allow a detailed systems pharmacology or response surface model approach. Trial registration www.isrctn.com; registration number ISRCTN53019164.
- 30 January 2024
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 44 (6) , 438-444
Comparative simulation of intraperitoneal aminoglycoside regimens for patients with peritonitis on automated peritoneal dialysis
Background: Intraperitoneal (IP) aminoglycosides (AGs) continue to be the cornerstone of empiric management of peritonitis. AG dosing during automated peritoneal dialysis (APD), however, has not been well studied in patients with peritonitis. We sought to identify differences in AG exposure in the peritoneum and plasma for two different dosing regimens with little supporting evidence in patients on APD with peritonitis. Methods: A retrospective design that utilised the peritoneal and plasma concentration–time data from a prior study of 18 continuous ambulatory peritoneal dialysis (CAPD) patients with peritonitis to generate an in silico peritoneal and plasma PK model. This model was then used to compare via simulation using Phoenix© WinNonlin Software with IP AG dosing for a loading-dose regimen (1.5 mg/kg first dose) versus a fixed-dose regimen (0.6 mg/kg/d) in patients on APD with peritonitis. Results: Outcome measures were (1) percentage of time where peritoneal peak concentrations/minimal inhibitory concentration (MIC) ratio >10, (2) AUC/MIC > 74 and (3) plasma Cmin concentrations. Both regimens resulted in > 90% optimal peak/MIC ratio and AUC/MIC ratios on days 1 and 5 of the dose protocol. The loading-dose regimen resulted in IP exposures that were 2.5 times greater in the peritoneal compartment on day 1. By day 5, both protocols resulted in similar accumulation of AG plasma Cmin concentrations of 2.5–3.4 mg/L versus 2.4–3.3 mg/L, respectively, for the loading-dose regimen versus fixed-dose regimen. Conclusions: The current international guidelines for the treatment of peritoneal dialysis-associated peritonitis can continue to recommend the fixed-dose regimen for those on APD with the addition of plasma Cmin monitoring after 3 days to assess for drug accumulation.
- 30 January 2024
- Published by SAGE Publications in Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis
- Vol. 44 (6) , 438-444
Comparative simulation of intraperitoneal aminoglycoside regimens for patients with peritonitis on automated peritoneal dialysis
Background: Intraperitoneal (IP) aminoglycosides (AGs) continue to be the cornerstone of empiric management of peritonitis. AG dosing during automated peritoneal dialysis (APD), however, has not been well studied in patients with peritonitis. We sought to identify differences in AG exposure in the peritoneum and plasma for two different dosing regimens with little supporting evidence in patients on APD with peritonitis. Methods: A retrospective design that utilised the peritoneal and plasma concentration–time data from a prior study of 18 continuous ambulatory peritoneal dialysis (CAPD) patients with peritonitis to generate an in silico peritoneal and plasma PK model. This model was then used to compare via simulation using Phoenix© WinNonlin Software with IP AG dosing for a loading-dose regimen (1.5 mg/kg first dose) versus a fixed-dose regimen (0.6 mg/kg/d) in patients on APD with peritonitis. Results: Outcome measures were (1) percentage of time where peritoneal peak concentrations/minimal inhibitory concentration (MIC) ratio >10, (2) AUC/MIC > 74 and (3) plasma Cmin concentrations. Both regimens resulted in > 90% optimal peak/MIC ratio and AUC/MIC ratios on days 1 and 5 of the dose protocol. The loading-dose regimen resulted in IP exposures that were 2.5 times greater in the peritoneal compartment on day 1. By day 5, both protocols resulted in similar accumulation of AG plasma Cmin concentrations of 2.5–3.4 mg/L versus 2.4–3.3 mg/L, respectively, for the loading-dose regimen versus fixed-dose regimen. Conclusions: The current international guidelines for the treatment of peritoneal dialysis-associated peritonitis can continue to recommend the fixed-dose regimen for those on APD with the addition of plasma Cmin monitoring after 3 days to assess for drug accumulation.
- Open Access
- 8 September 2023
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 55 (3) , 121-129
Anticoagulation strategies in COVID-19 infected patients receiving ECMO support
Background: Hospitalized COVID-19 patients with hypoxemic respiratory failure may deteriorate despite invasive mechanical ventilation and thus require extracorporeal membrane oxygenation (ECMO) support. Unfractionated heparin (UFH) is the antithrombotic of choice, however, bivalirudin may offer more predictable pharmacokinetics resulting in consistent anticoagulant effects with lower bleeding and thrombotic occurrences. The aim of this study was to evaluate efficacy and safety outcomes in patients undergoing venovenous (VV) ECMO receiving bivalirudin or UFH-based anticoagulation. Methods: This retrospective, single-center, observational cohort study included patients with confirmed COVID-19 infection requiring VV ECMO support receiving anticoagulation with UFH or bivalirudin. Primary endpoints were time to reach therapeutic aPTT, percent time spent in aPTT range, and the occurrence of thrombotic events over the entire course of ECMO support. Secondary endpoints included the incidence of major/minor bleeding, the ability to wean off ECMO support, in-hospital mortality, and length of stay. Results: Twenty-two patients were included in the study (n = 10 UFH, n = 12 bivalirudin). Time to therapeutic aPTT was achieved faster with UFH (10 h vs. 20 h). The percentage time spent within the goal aPTT range was similar between UFH and bivalirudin (50% vs. 52%). Thrombotic events were significantly higher in the UFH group (40% DVT, 40% PE, 80% oxygenator thrombus in ECMO machine, 10% ischemic stroke) versus bivalirudin (8% DVT, 17% PE, 33% oxygenator thrombus, no ischemic strokes) (CI 95%, p = 0.04). The overall bleeding incidence was higher in the UFH arm (90% vs. 75%). The mortality rate was 90% in the UFH group and 58% in the bivalirudin group. The length of stay was similar between the two study arms. Conclusion: In hospitalized patients with COVID-19-associated acute respiratory distress syndrome (ARDS) on VV ECMO support, the use of bivalirudin showed to be a viable anticoagulation alternative in terms of efficacy compared to UFH and resulted in a favorable safety profile with lower rates of bleeding and thrombotic events.
- 8 September 2023
- Published by EDP Sciences in The Journal of ExtraCorporeal Technology
- Vol. 55 (3) , 121-129
Open AccessAnticoagulation strategies in COVID-19 infected patients receiving ECMO support
Background: Hospitalized COVID-19 patients with hypoxemic respiratory failure may deteriorate despite invasive mechanical ventilation and thus require extracorporeal membrane oxygenation (ECMO) support. Unfractionated heparin (UFH) is the antithrombotic of choice, however, bivalirudin may offer more predictable pharmacokinetics resulting in consistent anticoagulant effects with lower bleeding and thrombotic occurrences. The aim of this study was to evaluate efficacy and safety outcomes in patients undergoing venovenous (VV) ECMO receiving bivalirudin or UFH-based anticoagulation. Methods: This retrospective, single-center, observational cohort study included patients with confirmed COVID-19 infection requiring VV ECMO support receiving anticoagulation with UFH or bivalirudin. Primary endpoints were time to reach therapeutic aPTT, percent time spent in aPTT range, and the occurrence of thrombotic events over the entire course of ECMO support. Secondary endpoints included the incidence of major/minor bleeding, the ability to wean off ECMO support, in-hospital mortality, and length of stay. Results: Twenty-two patients were included in the study (n = 10 UFH, n = 12 bivalirudin). Time to therapeutic aPTT was achieved faster with UFH (10 h vs. 20 h). The percentage time spent within the goal aPTT range was similar between UFH and bivalirudin (50% vs. 52%). Thrombotic events were significantly higher in the UFH group (40% DVT, 40% PE, 80% oxygenator thrombus in ECMO machine, 10% ischemic stroke) versus bivalirudin (8% DVT, 17% PE, 33% oxygenator thrombus, no ischemic strokes) (CI 95%, p = 0.04). The overall bleeding incidence was higher in the UFH arm (90% vs. 75%). The mortality rate was 90% in the UFH group and 58% in the bivalirudin group. The length of stay was similar between the two study arms. Conclusion: In hospitalized patients with COVID-19-associated acute respiratory distress syndrome (ARDS) on VV ECMO support, the use of bivalirudin showed to be a viable anticoagulation alternative in terms of efficacy compared to UFH and resulted in a favorable safety profile with lower rates of bleeding and thrombotic events.
- 16 May 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 329 (19) , 1703-1704
Torsemide vs Furosemide After Discharge and All-Cause Mortality in Patients With Heart Failure
To the Editor JAMA recently published the TRANSFORM-HF study,1 which reported that torsemide was no better than furosemide in preventing death due to heart failure in patients with chronic heart failure. The authors urged caution in interpretation of the null result and listed a number of issues with the study, including loss to follow-up, participant crossover, and dosing adherence. However, I believe they overlooked an important aspect of torsemide that could have been responsible for failure to demonstrate a benefit in TRANSFORM-HF.
- 16 May 2023
- Published by American Medical Association (AMA) in JAMA
- Vol. 329 (19) , 1703-1704
Torsemide vs Furosemide After Discharge and All-Cause Mortality in Patients With Heart Failure
To the Editor JAMA recently published the TRANSFORM-HF study,1 which reported that torsemide was no better than furosemide in preventing death due to heart failure in patients with chronic heart failure. The authors urged caution in interpretation of the null result and listed a number of issues with the study, including loss to follow-up, participant crossover, and dosing adherence. However, I believe they overlooked an important aspect of torsemide that could have been responsible for failure to demonstrate a benefit in TRANSFORM-HF.
- 22 October 2021
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 37 (12) , 607
Correction to: Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
- 22 October 2021
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 37 (12) , 607
Correction to: Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
- 6 October 2021
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 37 (12) , 581-589
Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
- 6 October 2021
- Published by Springer Nature in Drugs & Therapy Perspectives
- Vol. 37 (12) , 581-589
Intranasal metoclopramide for acute and recurrent diabetic gastroparesis in adults
- 1 July 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (9) , 1677-1678
Simulation of Drug in the Lung Can Be Misleading
- 1 July 2020
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 72 (9) , 1677-1678
Simulation of Drug in the Lung Can Be Misleading
- 21 May 2019
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 44 (5) , 691-711
Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers
Lack of information on the pharmacokinetics of the active moiety of Cannabis or the metabolites of delta-9-tetrahydrocannabinol (THC) does not seem to be discouraging medical or recreational use. Cytochrome P450 (CYP) 2C9, the primary enzyme responsible for THC metabolism, has two single nucleotide polymorphisms—Arg144Cys (*2) and Ile359Leu (*3). In the Caucasian population, allelic frequency is between 0.08 and 0.14 for CYP2C9*2 and between 0.04 and 0.16 for CYP2C9*3. In vitro data suggest that metabolic capacity for the variants CYP2C9*2 and CYP2C9*3 is about one-third compared to wild-type CYP2C9. Previous work has suggested exposure to the terminal metabolite is genetically determined. We therefore sought to characterize the pharmacokinetics of THC and its major metabolites 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in healthy volunteers with known CYP2C9 status by non-compartmental analysis (NCA), compartmental modeling (CM) and minimal physiologically based pharmacokinetic (mPBPK) modeling.
- 21 May 2019
- Published by Springer Nature in European Journal of Drug Metabolism and Pharmacokinetics
- Vol. 44 (5) , 691-711
Minimal Physiologically Based Pharmacokinetic Model of Intravenously and Orally Administered Delta-9-Tetrahydrocannabinol in Healthy Volunteers
Lack of information on the pharmacokinetics of the active moiety of Cannabis or the metabolites of delta-9-tetrahydrocannabinol (THC) does not seem to be discouraging medical or recreational use. Cytochrome P450 (CYP) 2C9, the primary enzyme responsible for THC metabolism, has two single nucleotide polymorphisms—Arg144Cys (*2) and Ile359Leu (*3). In the Caucasian population, allelic frequency is between 0.08 and 0.14 for CYP2C9*2 and between 0.04 and 0.16 for CYP2C9*3. In vitro data suggest that metabolic capacity for the variants CYP2C9*2 and CYP2C9*3 is about one-third compared to wild-type CYP2C9. Previous work has suggested exposure to the terminal metabolite is genetically determined. We therefore sought to characterize the pharmacokinetics of THC and its major metabolites 11-hydroxy-delta-9-tetrahydrocannabinol (THC-OH) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol (THC-COOH) in healthy volunteers with known CYP2C9 status by non-compartmental analysis (NCA), compartmental modeling (CM) and minimal physiologically based pharmacokinetic (mPBPK) modeling.
- 1 June 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (6) , 701-711
Allocation of faculty and curricular time to the teaching of transitions of care concepts by colleges of pharmacy
- 1 June 2018
- Published by Elsevier in Currents in Pharmacy Teaching and Learning
- Vol. 10 (6) , 701-711
Allocation of faculty and curricular time to the teaching of transitions of care concepts by colleges of pharmacy